| Literature DB >> 27930354 |
Boris Rudic1,2, Maria Chaykovskaya3, Alexey Tsyganov3, Vitaly Kalinin4, Erol Tülümen5,2, Theano Papavassiliu5,2, Christina Dösch5,2, Volker Liebe5,2, Jürgen Kuschyk5,2, Susanne Röger5,2, Ibrahim El-Battrawy5,2, Ibrahim Akin5,2, Marina Yakovleva3, Elena Zaklyazminskaya3,6, Anna Shestak3, Stanislav Kim3, Mikhail Chmelevsky4, Martin Borggrefe5,2.
Abstract
BACKGROUND: The underlying mechanisms of Brugada syndrome (BrS) are not completely understood. Recent studies provided evidence that the electrophysiological substrate, leading to electrocardiogram abnormalities and/or ventricular arrhythmias, is located in the right ventricular outflow tract (RVOT). The purpose of this study was to examine abnormalities of epicardial and endocardial local unipolar electrograms by simultaneous noninvasive mapping in patients with BrS. METHODS ANDEntities:
Keywords: Brugada syndrome; ajmaline challenge; arrhythmia; depolarization; electrocardiography; endocardium; epicardium; repolarization; right bundle branch block; right ventricular outflow tract; sudden death
Mesh:
Substances:
Year: 2016 PMID: 27930354 PMCID: PMC5210320 DOI: 10.1161/JAHA.116.004095
Source DB: PubMed Journal: J Am Heart Assoc ISSN: 2047-9980 Impact factor: 5.501
Baseline Characteristics and Genetic Data of Patients With Brugada Syndrome
| N | Sex | Age, y | Br Pattern on ECG |
| VT/VF | |||
|---|---|---|---|---|---|---|---|---|
| Baseline | Ajmaline Test | Mutation | Mutation Type | in History | During EP Study | |||
| 1 | Male | 56 | Type 1 | Not performed | c.IVS24+1G>A | Splicing | Yes | Not performed |
| 2 | Male | 33 | Type 1 | Not performed | p.R893H | Missense | No | Yes |
| 3 | Male | 41 | Type 1 | Not performed | p.S1787N | Missense | No | No |
| 4 | Male | 25 | Type 1 | Not performed | p.E553 | Nonsense | No | No |
| 5 | Male | 53 | Type 1 | Not performed | p.E553 | Nonsense | Yes | Not performed |
| 6 | Female | 41 | Type 2 | Positive | c.1233del | Frameshift deletion | No | Yes |
| 7 | Male | 33 | Type 2 | Positive | None | — | Yes | Not performed |
| 8 | Male | 32 | Type 2 | Positive | None | — | No | No |
| 9 | Female | 20 | Type 2 | Positive | None | — | No | No |
| 10 | Male | 45 | Type 1 | Not performed | None | — | No | Yes |
| 11 | Male | 31 | Type 2 | Positive | None | — | No | No |
| 12 | Male | 36 | Type 2 | Positive | None | — | No | No |
Br indicates Brugada; ECG, electrocardiogram; EP, electrophysiology; VF, ventricular fibrillation; VT, ventricular tachycardia.
Figure 1Recordings of local unipolar electrograms are presented (anterior and posterior view). Epicardial model on the left and endocardial model on the right, where calculations were derived from different sites of the left and right ventricle. LV indicates left ventricle; RV, right ventricle; RVOT, right ventricular outflow tract.
EGs Properties in the RVOT for BrS Patients, RBBB Patients, and Control Subjects
| Parameters | Cardiac Surface | BrS Patients With Spontaneous Type 1 (n=6) | BrS Patients With Nondiagnostic ECG Before Administration of Ajmaline (n=6) | BrS Patients With Nondiagnostic ECG After Administration of Ajmaline (n=6) | Patients With RBBB (n=6) | Control Subjects (n=15) |
|---|---|---|---|---|---|---|
| Area of EGs with elevated ST segment, cm2 | Epi | 32.0±25.8 | 13.3±8.6 | 31.4±15.35 | 0.0±0.0 | 0.0±0.0 |
| Endo | 19.8±15.6 | 20.6±16.9 | 27.6±12.1 | 0.0±0.0 | 0.0±0.0 | |
| Area of EGs with fragmentation, cm2 | Epi | 19.3±7.2 | 11.9±4.8 | 19.5±8.2 | 0.0±0.0 | 0.0±0.0 |
| Endo | 8.6±11.7 | 0.3±0.8 | 4.6±9.5 | 0.0±0.0 | 0.0±0.0 | |
| QRS voltage, mV | Epi | 19.8±16.3 | 17.7±7.0 | 18.6±4.9 | 17.2±9.5 | 22.6±8.0 |
| Endo | 26.4±19.6 | 29.6±18.1 | 29.2±9.0 | 23.8±14.6 | 29.3±18.3 | |
| Peak ST segment elevation, mV | Epi | 6.3±5.6 | 1.3±1.7 | 4.8±3.8 | 1.0±0.6 | 0.9±0.4 |
| Endo | 5.8±4.0 | 2.8±3.1 | 8.0±9.1 | 1.3±0.8 | 1.4±0.7 | |
| Activation time, ms | Epi | 65±19 | 60±9 | 78±12 | 102±14 | 50±13 |
| Endo | 65±20 | 53±7 | 85±20 | 91±19 | 38±13 | |
| Activation‐recovery interval, ms | Epi | 281±34 | 247±50 | 323±43 | 244±28 | 247±26 |
| Endo | 297±13 | 262±60 | 311±68 | 267±53 | 271±51 | |
| QRS duration, ms | 117±29 | 97±14 | 136±37 | 168±29 | 79±9 | |
| Interventricular delay, ms | 14±9 | 13±8 | 25±9 | 38±11 | 12±7 | |
| Epicardial‐endocardial voltage gradient, mV | −3.2±3.2 | −0.6±0.5 | −1.8±1.1 | 0.6±0.3 | −0.4±0.3 | |
BrS indicates Brugada syndrome; ECG, electrocardiogram; EGs, electrograms; Endo, endocardial; Epi, epicardial; RBBB, right bundle branch block; RVOT, right ventricular outflow tract.
P<0.05 when comparing variables between BrS and control subjects and between RBBB patients and control subjects.
P<0.05 when comparing variables between BrS and RBBB patients.
P<0.05 when comparing variables between BrS patients before and after ajmaline administration.
Figure 2Recordings of local unipolar electrograms of a BrS patient with a type 1 ECG are presented. Epicardial model on the left and endocardial model on the right, where calculations were derived from different sites of the left and right ventricle (see text for detailed description). BrS indicates Brugada syndrome; ECG, electrocardiogram; LV, left ventricle; RV, right ventricle; RVOT, right ventricular outflow tract.
Figure 3Epi‐Endo voltage gradient at end of the ventricular depolarization in a patient with BrS and type‐1 ECG (A), in a patient with RBBB (B) and in a control subject (C). Four of 6 patients with type 1 ECG, 1 of 5 patients with type 2 ECG before ajmaline administration, and 4 of 6 patient after ajmaline administration demonstrated negative Epi‐Endo VG (−2.5 to −6.0 mV) in the anterior‐lateral part of the RVOT (A). In contrast, during the same period, all control subjects had uniform weak negative Epi‐Endo VG in the entire surface of the RV (C). All RBBB patients had uniform weak positive Epi‐Edo VG in the entire surface of the RV (B). ECG, electrocardiogram; Epi‐Endo, epicardial and endocardial; RBBB, right bundle branch block; RV, right ventricle; RVOT, right ventricular outflow tract; VG, voltage gradient.
EGs Properties in the RVOT for BrS Patient Subgroups
| Parameters | Cardiac Surface | Patients Without VF (N=6) | Patients With VF (N=6) |
|---|---|---|---|
| Area of EGs with elevated ST segment, cm2 | Epi | 20.2±20.3 | 42.2±14.2 |
| Endo | 18.2±17.5 | 29.2±6.9 | |
| Area of EGs with fragmentation, cm2 | Epi | 20.8±8.5 | 17.0±6.4 |
| Endo | 6.5±12.5 | 6.7±9.0 | |
| QRS voltage, mV | Epi | 26.8±10.7 | 11.6±6.2 |
| Endo | 31.0±10.3 | 14.6±7.2 | |
| Peak ST segment elevation, mV | Epi | 6.0±5.7 | 5.1±3.7 |
| Endo | 5.3±6.0 | 8.5±7.7 | |
| Activation time, ms | Epi | 87±21 | 62±14 |
| Endo | 79±13 | 64±17 | |
| Activation‐recovery interval, ms | Epi | 296±35 | 308±52 |
| Endo | 284±42 | 314±53 | |
| QRS duration, ms | 126±21 | 126±21 | |
| Interventricular delay, ms | 14±7 | 14±7 | |
| Epicardial‐endocardial voltage gradient, mV | −3.4±3.1 | −3.4±3.1 | |
BrS indicates Brugada syndrome; EGs, electrograms; Endo, endocardial; Epi, epicardial; RVOT, right ventricular outflow tract; VF, ventricular fibrillation.
P<0.05 when comparing variables between symptomatic and asymptomatic BrS patients.